The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome

Gut

Volumn 59, Issue 9, 2010, Pages 1213-1221

  Klooker, Tamira K ^a   Braak, Breg ^a   Koopman, Karin E ^a   Welting, Olaf ^a   Wouters, Mira M ^b   Van Der Heide, Sicco ^c   Schemann, Michael ^d   Bischoff, Stephan C ^e   Van Den Wijngaard, Rene M ^a   Boeckxstaens, Guy E ^a,b  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e UNIVERSITY OF HOHENHEIM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HISTAMINE; KETOTIFEN; PLACEBO; TRYPTASE; HISTAMINE H1 RECEPTOR ANTAGONIST;

ADOLESCENT; ADULT; ARTICLE; BAROSTAT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPERSENSITIVITY; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; MAST CELL; NERVOUSNESS; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECTUM; RECTUM BIOPSY; SIDE EFFECT; XEROSTOMIA; AGED; CELL COUNT; DRUG EFFECTS; ELASTICITY; HISTAMINE RELEASE; INNERVATION; IRRITABLE BOWEL SYNDROME; METABOLISM; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PERCEPTIVE THRESHOLD; PHYSIOLOGY; PRESSURE; TREATMENT OUTCOME; VISCERA; YOUNG ADULT;

ADULT; AGED; CELL COUNT; DOUBLE-BLIND METHOD; ELASTICITY; FEMALE; HISTAMINE H1 ANTAGONISTS; HISTAMINE RELEASE; HUMANS; IRRITABLE BOWEL SYNDROME; KETOTIFEN; MALE; MAST CELLS; MIDDLE AGED; PRESSURE; QUALITY OF LIFE; RECTUM; SENSORY THRESHOLDS; TREATMENT OUTCOME; TRYPTASES; VISCERA; YOUNG ADULT;

EID: 77956102855     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2010.213108     Document Type: Article

References (38)

1. Mayer EA, Bradesi S, Chang L, et al. Functional GI disorders: from animal models to drug development. Gut 2008;57:384-404.
2. Camilleri M, Busciglio I, Carlson P, et al. Candidate genes and sensory functions in health and irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol 2008;295:G219-25.
3. Santos J, Alonso C, Guilarte M, et al. Targeting mast cells in the treatment of functional gastrointestinal disorders. Curr Opin Pharmacol 2006;6:541-6.
4. Guilarte M, Santos J, de Torres I, et al. Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum. Gut 2007;56:203-9.
5. Piche T, Saint-Paul MC, Dainese R, et al. Mast cells and cellularity of the colonic mucosa correlated with fatigue and depression in irritable bowel syndrome. Gut 2008;57:468-73.
6. Barbara G, Stanghellini V, De GR, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004;126:693-702.
7. Park JH, Rhee PL, Kim HS, et al. Mucosal mast cell counts correlate with visceral hypersensitivity in patients with diarrhea predominant irritable bowel syndrome. J Gastroenterol Hepatol 2006;21:71-8.
8. Cenac N, Andrews CN, Holzhausen M, et al. Role for protease activity in visceral pain in irritable bowel syndrome. J Clin Invest 2007;117:636-47.
9. Barbara G, Wang B, Stanghellini V, et al. Mast cell-dependent excitation of visceralnociceptive sensory neurons in irritable bowel syndrome. Gastroenterology 2007;132:26-37.
10. Gue M, Del Rio-Lacheze C, Eutamene H, et al. Stress-induced visceral hypersensitivity to rectal distension in rats: role of CRF and mast cells. Neurogastroenterol Motil 1997;9:271-9. (Pubitemid 27499531)
11. Rijnierse A, Nijkamp FP, Kraneveld AD. Mast cells and nerves tickle in the tummy: implications for inflammatory bowel disease and irritable bowel syndrome. Pharmacol Ther 2007;116:207-35.
12. Serna H, Porras M, Vergara P. Mast cell stabilizer ketotifen [4-(1-methyl-4-piperidylidene)-4h-benzo[4,5]cyclohepta[1,2-b]thiophen-10(9 H)-one fumarate] prevents mucosal mast cell hyperplasia and intestinal dysmotility in experimental Trichinella spiralis inflammation in the rat. J Pharmacol Exp Ther 2006;319:1104-11.
13. Marshall JK, Irvine EJ. Ketotifen treatment of active colitis in patients with 5-aminosalicylate intolerance. Can J Gastroenterol 1998;12:273-5.
14. Kuiken SD, Lindeboom R, Tytgat GN, et al. Relationship between symptoms and hypersensitivity to rectal distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2005;22:157-64.
15. Klooker TK, Kuiken SD, Lei A, et al. Effect of long-term treatment with octreotide on rectal sensitivity in patients with non-constipated irritable bowel syndrome. Aliment Pharmacol Ther 2007;26:605-15. (Pubitemid 47174283)
16. Schwartz LB, Bradford TR, Rouse C, et al. Development of a new, more sensitive immunoassay for human tryptase: use in systemic anaphylaxis. J Clin Immunol 1994;14:190-204.
17. Svedlund J, Sjodin I, Dotevall G. GSRS - a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci 1988;33:129-34.
18. Kuiken SD, Tytgat GN, Boeckxstaens GE. The selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: a double blind, randomized, placebo-controlled study. Clin Gastroenterol Hepatol 2003;1:219-28.
19. Buhner S, Li Q, Vignali S, et al. Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome. Gastroenterology 2009;137:1425-34.
20. Kuiken SD, Klooker TK, Tytgat GN, et al. Possible role of nitric oxide in visceral hypersensitivity in patients with irritable bowel syndrome. Neurogastroenterol Motil 2006;18:115-22.
21. Simren M, Simms L, D'Souza D, et al. Lipid-induced colonic hypersensitivity in irritable bowel syndrome: the role of 5-HT3 receptors. Aliment Pharmacol Ther 2003;17:279-87.
22. Delvaux M, Louvel D, Lagier E, et al. The kappa agonist fedotozine relieves hypersensitivity to colonic distention in patients with irritable bowel syndrome. Gastroenterology 1999;116:38-45. (Pubitemid 29013491)
23. Mayer EA, Bradesi S. Alosetron and irritable bowel syndrome. Expert Opin Pharmacother 2003;4:2089-98.
24. Naliboff BD, Berman S, Suyenobu B, et al. Longitudinal change in perceptual and brain activation response to visceral stimuli in irritable bowel syndrome patients. Gastroenterology 2006;131:352-65.
25. Stefanini GF, Saggioro A, Alvisi V, et al. Oral cromolyn sodium in comparison with elimination diet in the irritable bowel syndrome, diarrheic type. Multicenter study of 428 patients. Scand J Gastroenterol 1995;30:535-41.
26. Bolin TD. Use of oral sodium cromoglycate in persistent diarrhoea. Gut 1980;21:848-50.
27. Lunardi C, Bambara LM, Biasi D, et al. Double-blind cross-over trial of oral sodium cromoglycate in patients with irritable bowel syndrome due to food intolerance. Clin Exp Allergy 1991;21:569-72.
28. McNeil HP, Adachi R, Stevens RL. Mast cell-restricted tryptases: structure and function in inflammation and pathogen defense. J Biol Chem 2007;282:20785-9.
29. Smith EA, Macfarlane GT. Studies on amine production in the human colon: enumeration of amine forming bacteria and physiological effects of carbohydrate and pH. Anaerobe 1996;2:285-97.
30. Schoch C. In vitro inhibition of human conjunctival mast-cell degranulation by ketotifen. J Ocul Pharmacol Ther 2003;19:75-81.
31. Grant SM, Goa KL, Fitton A, et al. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in asthma and allergic disorders. Drugs 1990;40:412-48. (Pubitemid 20287934)
32. Mitsuchashi M, Payan DG. Molecular and cellular analysis of histamine H1 receptors on cultured smooth muscle cells. J Cell Biochem 1989;40:183-92.
33. Akdis CA, Simons FE. Histamine receptors are hot in immunopharmacology. Eur J Pharmacol 2006;533:69-76.
34. Sander LE, Lorentz A, Sellge G, et al. Selective expression of histamine receptors H1R, H2R, and H4R, but not H3R, in the human intestinal tract. Gut 2006;55:498-504.
35. Brown RE, Stevens DR, Haas HL. The physiology of brain histamine. Prog Neurobiol 2001;63:637-72.
36. Watanabe S, Hattori T, Kanazawa M, et al. Role of histaminergic neurons in hypnotic modulation of brain processing of visceral perception. Neurogastroenterol Motil 2007;19:831-8.
37. Eutamene H, Theodorou V, Fioramonti J, et al. Acute stress modulates the histamine content of mast cells in the gastrointestinal tract through interleukin-1 and corticotropin-releasing factor release in rats. J Physiol 2003;553:959-66.
38. Farhadi A, Keshavarzian A, Fields JZ, et al. Reduced immunostaining for c-kit receptors in mucosal mast cells in inflammatory bowel disease. J Gastroenterol Hepatol 2007;22:2338-43. (Pubitemid 350145634)